LEGION-100: A Phase 1b Open-Label, Dose-Escalation Study of SYNC-T Therapy SV-102 in Patients Diagnosed With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

At a glance
Trial Overview
Trial Details
Interventions
Trial Centres
- Investigators
- Centres
Trial History
References

Trial Profile

LEGION-100: A Phase 1b Open-Label, Dose-Escalation Study of SYNC-T Therapy SV-102 in Patients Diagnosed With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SV 102 (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions
Acronyms LEGION-100
Sponsors Syncromune

Most Recent Events

04 Mar 2025 Planned initiation date changed from 1 Jan 2025 to 1 Mar 2025.
06 Jan 2025 Planned initiation date (estimated date of first participant enrollement) changed from 1 Nov 2024 to 1 Jan 2025.
06 Jan 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com